Rare lung infections: towards personalized care

Treatment of rare nontuberculous mycobacterial (NTM) pulmonary infections is prolonged and burdensome, and is not effective for all patients. Pulmonologist Sanne Zweijpfenning from Radboudumc is investigating how treatment can be improved. Her goal? A more personalized approach to treatment.

Man, winter adem

A rare lung infection with serious consequences

Some lung diseases are rare. As a result, they are sometimes diagnosed late, and little is often known about the most effective treatment. This is the case, for example, with nontuberculous mycobacterial (NTM) pulmonary infections. NTM refers to a group of bacteria that can cause chronic lung infections. These infections mainly affect people with pre-existing lung diseases, such as COPD. An NTM pulmonary infection can have a significant impact on daily life. Patients experience persistent coughing with mucus production and shortness of breath. Everyday activities, such as grocery shopping, walking, or spending time with family and friends, can become exhausting.

Sanne Zweijpfenning 2026

“By comparing different types of data, I hope to understand why some patients respond better to treatment than others.”

Dr. Sanne Zweijpfenning

A demanding treatment that is not always effective

NTM pulmonary infections are difficult to treat. Patients often need to take three or more antibiotics simultaneously for up to 18 months. This places a considerable burden on patients. The medications can cause unpleasant side effects, sometimes so severe that treatment has to be discontinued. Despite this prolonged treatment, the infection does not resolve in everyone. On average, only six out of ten patients are successfully treated. Pulmonologist Sanne Zweijpfenning believes there is room for improvement. Why does treatment work for some patients but not for others?

Not all patients are the same

Currently, patients with NTM pulmonary infections often receive similar treatment regimens. However, Zweijpfenning believes there are important differences between patients. She therefore aims to investigate the role of the immune system, which helps the body fight infections.

Together with her team, Zweijpfenning is studying the immune systems of approximately 200 patients with NTM pulmonary infections. She is also examining other clinical data, including blood test results, CT scans, and disease severity. By comparing all this information, she hopes to identify why some patients respond better to treatment than others.

Subsidie onderzoek

Longfonds-Swierenga Grant

Zweijpfenning has been awarded €50,000 through the Longfonds-Swierenga Grant. This grant, provided by Longfonds and the Swierenga Foundation, supports researchers in further developing innovative ideas for rare lung diseases. Because people living with rare lung diseases also deserve effective treatment, the opportunity to breathe more freely, and a better quality of life.

Towards personalized treatment

With this knowledge, Zweijpfenning aims to take an important step towards personalized care. Rather than applying the same approach to every patient, the goal is to provide treatment that is better tailored to each individual's needs and circumstances. Ultimately, the research aims to develop a clear clinical decision-making framework to help physicians determine the most appropriate treatment for each patient. This may involve a combination of antibiotics, as well as additional therapies to alleviate symptoms or support recovery. Patients with NTM pulmonary infections will also be actively involved in the research. By working together, researchers and patients hope to develop treatments that are not only more effective but also less burdensome.

Hope for the future

The research is still in its early stages, and the proposed clinical decision-making framework will need to be tested. Only then will researchers be able to determine whether this approach leads to better outcomes. Nevertheless, this represents an important first step. The better physicians understand why some patients respond to treatment while others do not, the greater the potential to provide more personalized and effective care in the future.